|Last Price$0.62||Day Change (%)-2.41%|
|Open Price$0.66||Day Change ($)-0.02|
|Day Range0.62–0.68||52-Week Range0.41–2.35|
As of Fri 10/24/2014 03:00 PM EST | USD
GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...
Garmin® Offers Simple, Stand-Alone ADS-B Solution For Business And Transport Aircraft
GAIN Capital Announces Monthly Metrics for September 2014
GE’s Evolve™ LED Security Light Saves Money and Maintenance Needs with Energy-Efficient Lighting
We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.
GTx adds a European partner.